Cipla shares fell up to 4% on October 30 after the pharma major announced that that it has elevated Achin Gupta, Global Chief Operating Officer, Cipla Limited to MD & global CEO effective April 1, 2026, for a term of 5 years.
"Achin has been appointed as MD & GCEO Designate from January 1st, 2026. Achin will succeed Umang Vohra who has served as the MD & GCEO of Cipla since 2016. This planned transition is in line with our succession process developed by the Board and Umang, ensuring continuity, stability, and a clear vision for the future," said Cipla in a stock exchange filing.
At 2 pm on October 30, Cipla shares on NSE were trading 2.6% lower at Rs 1,539 apiece and had hit intraday low of Rs 1,504.
Achin Gupta has been serving as the GCOO of the Company since February 2025, overseeing Commercial markets, API, Manufacturing, and Supply Chain. He joined Cipla in 2021 as the CEO of the One India business.
Achin Gupta holds a M Tech degree from IIT Delhi, specialising in Biochemical Engineering and Biotechnology and an MBA from IIM, Ahmedabad.
Umang Vohra who joined Cipla in 2015 as Global Chief Financial & Strategy Officer and thereafter served as Cipla’s MD & GCEO since 2016. "Over the past decade, Umang has led Cipla through a period of effective transformation, guided by the company’s purpose of Caring for Life. His leadership has been instrumental in driving strategic growth, financial performance, innovation, and operational excellence across the organisation," said Cipla.
Speaking on the announcement, YK Hamied, Chairman, Cipla Limited said, “I thank Umang for his stewardship over the last ten years, his outstanding contributions and dedication to Cipla’s purpose of Caring for Life and combining business with a humanitarian approach. We wish Umang continued success in his future career. We are pleased to welcome Achin Gupta as he steps into this role, and I am confident he will lead Cipla to its next phase of progress and growth."
Founded in 1935, Cipla is the third largest drugmaker in domestic market by sales and is one of India’s most storied drugmakers, known for its humanitarian approach to healthcare and landmark contributions to global access, including its $1-a-day HIV/AIDS therapy in Africa. The company operates 46 manufacturing sites and serves over 74 markets, ranking among the top players in India, South Africa, and the US generic inhalation space.
“Cipla’s legacy of patient-centric care is deeply inspiring,” Gupta said in a statement. “My focus will remain on driving sustainable growth, deepening our impact across markets, and continuing to innovate with purpose.”
Under Vohra, Cipla became a hugely profitable company. In FY25, Cipla posted consolidated revenue of Rs 27,548 crore, net profit of Rs 5,273 crore, and an EBITDA margin of 25.9%.
Cipla Q2 results
Cipla reported a net profit of Rs 1,351 crore for Q2FY26, marking a 4% year-on-year (YoY) rise from the Rs 1,302.53 crore net profit reported in Q2FY25. The net profit reported for the quarter however is lower than the Rs 1,387 crore net profit estimated on an average by brokerages polled by Moneycontrol.
The firm’s revenue from operations, meanwhile, rose 8 percent YoY to Rs 7,589.44 crore during the quarter under review. This is higher than the MC poll estimate of Rs 7,425 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
